FINWIRES · TerminalLIVE
FINWIRES

Bravo Mining股價上漲1.4%，此前該公司公佈了巴西Luanga項目的最新化驗結果。

By

-- Bravo Mining (BRVO.V) 週二公佈了巴西 Luanga 鈀鉑銠金鎳礦床中央區和新近勘探的新月區八個鑽孔的化驗結果。 亮點包括：70 公尺厚的礦層，鉑族金屬和金 (PGM+Au) 品位為 1.9 克/噸，鎳含量為 0.28%；其中 20 公尺厚的礦層，PGM+Au 品位為 3.6 公克/噸，鎳含量為 0.40%；19 公尺厚的礦層，PGM+ 公尺為 3.4 19 公尺厚的礦層。 1.94%，PGM+Au 品位為 0.6 克/噸。 Bravo 表示，這些結果繼續表明 Luanga 礦床的礦產資源具有擴大和升級的潛力。該公司還補充說，迄今已完成 400 個鑽孔，其中 355 個鑽孔的結果已公佈，另有 37 個鑽孔的化驗結果待公佈。 「加密鑽探持續截獲厚度和品位均與早期鑽探結果相當甚至更優的礦體。本新聞稿中的鑽探剖面圖也表明，品位持續穩定，鑽孔間和剖面間的連續性極佳，」董事長兼首席執行官路易斯·阿澤維多 (Luis Azevedo) 表示。 「新月形礦帶 (Crescent Zone) 的積極成果也令我們倍感鼓舞。該礦帶是位於盧安加 (Luanga) 三大鉑族金屬礦區之外的區域性目標。新月形礦帶是在 2025 年地球物理勘測完成後，通過重新解釋和重新測井而探索的銅形。此外，我們在新月礦帶東端，進一步勘探了333(DDH3)。 截至發稿時，BRVO 在加拿大的股價上漲了 1.4%。

Price: $3.55, Change: $+0.05, Percent Change: +1.43%

Related Articles

Commodities

Avista Q1 Energy Volumes Drop Across Segments Amid Softer Demand

Avista (AVA) reported Q1 earnings Tuesday, with electricity and natural gas volumes declining as milder weather reduced demand, with residential usage down 10% and commercial down 6%.The company reported total residential electricity sales through its operating unit, Avista Utilities, at 1.15 gigawatt-hours, down from 1.27 GWh a year earlier.Electricity sales to the commercial sector were 768 megawatt-hours for the quarter ended March 31, compared with 808 MWh a year earlier.The company reported industrial electricity sales for 455 MWh for the quarter, down from 469 MWh a year earlier, while wholesale sales were 912 MWh, down from 951 MWh a year earlier.The company reported total residential natural gas sales through its operating unit, Avista Utilities, of 8,490.7 billion British thermal units delivered, down from 9,888.1 billion Btu delivered a year earlier.Commercial natural gas sales were 5,116.1 billion Btu delivered for the quarter ended March 31, compared with 5,961.9 billion Btu delivered a year earlier.The company reported wholesale natural gas volumes of 5,446.1 billion Btu delivered in Q1, down from 6,752.8 billion Btu delivered a year earlier.Other natural gas volumes were 5,446.1 billion Btu delivered for the quarter, compared with 5,401.9 billion Btu delivered a year earlier.Avista is also advancing a new enterprise resource planning system targeted for completion in 2028, with estimated capital expenditures of about $130 million to enhance operational efficiency and financial reporting capabilities.Price: $40.81, Change: $+0.25, Percent Change: +0.62%

$AVA
Australia

Primo Brands' Q1 Faces Pressure From Service Disruptions, Cost Headwinds, RBC Says

Primo Brands (PRMB) is expected to face pressure in Q1 from extended service disruptions tied to winter storms and higher input costs linked to the Middle East conflict, RBC Capital Markets said in a note emailed Tuesday.The firm said Q1 is likely to be the weakest quarter of the year and could be further affected by lost or unrecoverable delivery sales from the winter storms.Retail business trends appear supportive, with sales growth of 6% in scanner data, RBC said, adding that the company has taken pricing on about 15% of its retail volume outside its core case pack business.Primo Brands also remains highly sensitive to petroleum-linked costs, including resin, glass, aluminum and diesel fuel, though it has significant hedge coverage in place for 2026 and levers such as pricing and fuel surcharges, the note said.Primo Brands is expected to report Q1 financial results on Thursday.RBC maintained its outperform rating on Primo Brands and kept its price target at $28.Price: $20.37, Change: $+0.27, Percent Change: +1.37%

$PRMB
Australia

BioMarin Enters 'Transition Year' as Enzyme Portfolio Expands After Amicus Deal, Morgan Stanley Says

BioMarin Pharmaceutical (BMRN) is entering a "transition year" in 2026, prioritizing growth acceleration and market share gains as its expanded enzyme portfolio scales following the acquisition of Amicus Therapeutics (FOLD), Morgan Stanley said in a report Tuesday.In its Q1 results, BioMarin raised its fiscal 2026 revenue guidance to $3.825 billion to $3.925 billion, driven by contributions from newly added therapies Galafold and Pombiliti plus Opfolda, but lowered its non-GAAP earnings per share outlook to $4.85 to $5.05 due to integration-related costs and higher interest expenses, associated with the transaction, the report said.BioMarin is focused on scaling its expanded enzyme portfolio and driving commercial execution, with its management expected to outline a detailed roadmap in Q2 covering "long-term revenue potential," peak sales and cost synergies, the investment bank said.Earnings are expected to be weighted toward the second half of 2026, with the Amicus deal seen by the management as "slightly dilutive" this year but "accretive" within 12 months and more meaningful in start of 2027, the report said.The "combined enzyme portfolio" is expected to support durable growth and help offset rising competition for Voxzogo, while pipeline developments and new launches, including Palynziq expansion and BMN-333, could further support long-term growth, according to the report.Morgan Stanley has an overweight rating on BioMarin Pharmaceutical and lowered its price target to $119 from $120.Price: $54.26, Change: $-1.20, Percent Change: -2.16%

$BMRN$FOLD